Conclusions With the exception of one large network, RDS was not a particularly efficient way to screen for Ct/GC. Only one-fourth of those initially recruited by research staff in turn referred their sexual and sexual contacts. While social network testing has been adopted in the HIV testing realm, in the Ct/GC screening realm a focus on messages encouraging those who are tested to get their friends tested may have the greatest public health impact.

**S14.5 TREPONEMA PALLIDUM σ24 REGULON AND ENVELOPE STRESS RESPONSE**

doi:10.1136/sextrans-2011-050102.60

L Giacani, O Denisenko, M Tompa, B Molini, A Centurion-Lara. University of Washington, Seattle, Washington, USA

**Background** During syphilis infection, the envelope of *T. pallidum* is constantly exposed to the host environment and, therefore, the most likely target of the host defences against the invading spirochaete. The mechanisms that maintain *T. pallidum* envelope integrity and functionality, particularly in response to host-induced stresses, are however poorly understood, and their elucidation would likely help identify important pathogenesis-associated molecules, perhaps related to *T. pallidum*’s ability to persist in the host despite a robust immune response. We hypothesised that in *T. pallidum*, similarly to other Gram-negative pathogens, the transcription factor σ24 (σ24, encoded by the rpoE gene, T00092) might be a key element in maintaining *T. pallidum* envelope homeostasis. Putative σ24 binding motifs can be identified in silico upstream of several *T. pallidum* genes that were experimentally shown to be involved in envelope stress response (ESR) in *Escherichia coli*. Furthermore, during early experimental syphilis σ24 is highly transcribed compared to other σ factors, and its expression increases even more as primary infection progresses. We therefore decided to investigate the possible role of σ24 in *T. pallidum* ESR by identifying the components of the *T. pallidum* σ24 regulon. **Methods** *T. pallidum* cells grown in rabbits were fixed after harvest to crosslink DNA-binding proteins to their target sequences in the chromosome. DNA sequences recognised by σ24 in vivo were isolated using chromatin immunoprecipitation in combination with high-throughput DNA sequencing (ChIP-seq) to identify bound DNA regions. **Results** Thirty-nine DNA fragments targeted by σ24 were identified in the *T. pallidum* chromosome. Seven of these target genes (lon-1, greA, ftsZ, prbB, lacA, and rpoE) were previously reported to be induced in response to envelope stress in *E. coli*, suggesting that the *T. pallidum* σ24 regulon is likely to be similar to that of other bacteria. Other putative target genes encode transporters, cell division proteins and a subset of motility and chemotaxis proteins. **Conclusions** In *T. pallidum*, σ24 seems to control genes involved in a variety of cellular processes, including maintenance of envelope homeostasis and barrier function. Additional putative σ24-dependent functions, apparently not directly involved in ESR, could as well be important in helping *T. pallidum* adapt to the host environment during the infection.

**S14.6 PREVALENCE AND PREDICTORS OF TRICHOMONAS INFECTION IN INCARCERATED WOMEN**

doi:10.1136/sextrans-2011-050102.61

1A Nijhawan, 2R Salloway, 2S Andrea, 4J Champion, 5M Seadale, 2,8K Chapin, 2,4J G Clarke. Harvard Medical School, Boston, Massachusetts, USA; 3Memorial Hospital of Rhode Island, Pawtucket, USA; 2Rhode Island Hospital, Providence, USA; 4Brown University, Providence, USA; 5Miriam Hospital, Providence, USA; 6Alpert School of Medicine at Brown University, Pawtucket, USA

**Background** *Trichomonas vaginalis* is the most prevalent curable sexually transmitted infection in the United States and may lead to preterm delivery, infertility and increased HIV transmission. Illicit drug use, HIV infection and Black race have been associated with high rates of infection. Incarcerated women may be at especially high risk for infection, though few studies have examined routine screening for trichomonas in this population. **Methods** Women >18-years-old entering the Rhode Island Department of Corrections between September 2009 and December 2010 were recruited to participate. All women submitted a self-collected vaginal swab for trichomonas culture and Transcription Mediated Amplification testing. Each participant completed a survey addressing demographics, symptoms, sexual behaviour, and substance use by audio computer-assisted self-interview. Data analysis was completed using multivariate logistic regression in STATA. **Results** 288 women enrolled in the study, mean age was 28 years. 59% of participants were White, 17% Hispanic, 12% Black and 12% other races. Forty-three per cent reported vaginal symptoms and 54% reported illicit drug use in the 30 days prior to incarceration. Among all participants, the prevalence of trichomonas was 8.7% by culture and 12.5% by NAAT. The strongest predictors of infection included Black race (OR 4.1, 95% CI 1.4 to 12.0), cocaine use in the 30 days prior to incarceration (OR 2.5, 95% CI 1.1 to 5.7), and >3 years since last pap smear (OR 5.2, 95% CI 1.5 to 17.8). Vaginal symptoms and age were not significantly associated with trichomonas detection. **Conclusions** Trichomonas infection is common in incarcerated women, especially among Blacks, recent cocaine users and those not receiving routine gynaecologic care. Infection was not predicted by symptoms or by age. Routine screening for trichomonas infection in high-risk populations may lead to increased detection and treatment.

**S15 STI epidemiology in Europe: challenges for prevention and control**

**S15.1 SEXUALLY TRANSMITTED INFECTIONS IN EUROPE: COORDINATING THE EUROPEAN STI NETWORK**

doi:10.1136/sextrans-2011-050102.62

M van de Laar. European Centre for Disease Prevention and Control, Stockholm, Sweden

**Background** Since 2008, the European Centre for Disease Prevention and Control is coordinating the enhanced STI surveillance in 30 EU/EEA countries. Each country was requested to nominate experts for collaboration and data submission to the European Surveillance System. Five STI are under surveillance, syphilis, congenital syphilis, gonorrhoea, chlamydia and LGV, as per Decision 2119/98/EC of the European Commission. **Methods** Surveillance objectives and the set of variables for enhanced STI surveillance were agreed upon in the annual network meeting and training session to use the European Surveillance System for data submission. Data were collected for the period 1990–2009; two network meetings were organised for all 30 EU/EEA countries to discuss the preliminary results. **Results** Chlamydia is the most frequently reported STI in Europe, accounting for the majority of all STI reports with 434 958 cases in 2009 (185 per 100 000 population). Chlamydia was reported more in women than in men and 75% were reported in young people (15 and 24 years). Chlamydia is increasing continuously over time. In 2009, 29 202 gonorrhoea cases have been reported (9.7/100 000) and nearly a quarter of all gonorrhoea cases were reported in MSM. For syphilis, 18 817 cases have been reported (4.5 per 100 000) and half of syphilis cases were reported in MSM. The overall trend in gonorrhoea and syphilis across the EU/EEA showed a notable decreasing trend in
countries which previously had reported very high rates. These declines are probably due to changes in healthcare systems, diagnostic capacity and reporting rather than true changes in the incidence. However, dramatic increases were noted in other countries and—based on the information from the male-to-female ratio—this is most likely due to recent increases of syphilis among MSM. The overall trend in chlamydia showed a continuously increasing trend, reflecting an increase in testing and screening practices across countries. These trends must be interpreted with caution due to the heterogeneity in reporting and healthcare systems. A further limitation to the interpretation is that many diagnoses are either not made or under-reported. Diagnoses from certain countries cannot be included in trend analyses as they do not have comprehensive surveillance for STI.

**Conclusion** Enhanced surveillance of STI in Europe is essential to provide the information that is necessary to monitor the distribution of disease and to evaluate the public health response to control the transmission of infections. Collaborating within the European STI expert networks provides the platform for sharing best practices across and expert knowledge beyond Europe.

**S15.2 EUROPEAN GONOCOCAL ANTIMICROBIAL SURVEILLANCE PROGRAMME (EURO-GASP): TOWARDS TIMELIER MONITORING**

doi:10.1136/sextrans-2011-050102.63

1M J Cole, 1S A Chisholm, 2M Unemo, 3S Hoffmann, 4M J W van de Laar, 1C A Ison.  
1Health Protection Agency, London, UK; 2Örebro University Hospital, Örebro, Sweden;  
3Statens Serum Institut, Copenhagen, Denmark; 4European Centre for Disease Prevention and Control, Stockholm, Sweden

**Background** It is imperative that antimicrobial resistance (AMR) surveillance systems work in a timely manner and outcomes are translated into treatment guidelines without delay. For the first time in 2010, the European gonococcal antimicrobial surveillance programme (Euro-GASP) introduced biannual testing to allow more frequent reporting of trends and developments in *Neisseria gonorrhoeae* AMR across Europe.

**Methods** In the first half of 2010, 18 out of the 30 EU/EEA Member States contributed up to 55 consecutive gonococcal isolates to Euro-GASP. Susceptibility testing was performed by Etest or agar dilution for therapeutically relevant antimicrobials: azithromycin, cefixime, ceftriaxone, ciprofloxacin, gentamicin and spectinomycin. Biannual testing continued into the second half of 2010. Additionally, 10 laboratories performed decentralised testing with the submission of AMR data into Euro-GASP instead of gonococcal isolates.

**Results** In the first round of biannual testing 900 *N. gonorrhoeae* isolates were tested. Eight per cent of the isolates displayed decreased susceptibility (>0.125 mg/l) to cefixime, which was an increase from 5% in 2009. No decreased susceptibility to ceftriaxone was detected. For ciprofloxacin, the overall incidence of resistant isolates decreased from 63% in 2009 to 52% in 2010 and azithromycin resistance decreased from 13% in 2009 to 5% in 2010. No resistance to spectinomycin was demonstrated. The MIC50 and MIC90 of gentamicin in the isolates remained at 8 mg/l in 2010.

**Conclusions** The results from the first round of biannual testing have shown that isolates displaying decreased susceptibility to cefixime are rapidly increasing. This is a major concern as cefixime is a widely used, recommended therapy for gonorrhoea across Europe. Healthcare professions should be aware of cefixime treatment failures, particularly in light of the recent identification of treatment failures in Norway and the UK. The MICs of ceftriaxone need to be monitored continually to preserve this precious treatment option. Euro-GASP is currently being adjusted to allow for timely reporting and decentralised testing including representativeness and links to epidemiological data. All of which contribute to monitoring the ever changing gonococcus in timelier and more efficient ways, with the ultimate aim of treating infected individuals successfully.

**S15.3 EUROPEAN MSM INTERNET SURVEY (EMIS): DIFFERENCES IN SEXUALLY TRANSMISSIBLE INFECTION TESTING IN EUROPEAN COUNTRIES**

doi:10.1136/sextrans-2011-050102.64

1U Marcus, 2A J Schmidt, 3M Breviglieri, 3F Davila, 2L Ferrer, 2C Folch, 2H Hickson,  
1H J Hasper, 2M Miranda, 3D Reid, 4P Weatherburn, for the EMIS network.  
1Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany; 2Regional Centre for Health Promotion, ULSS 20—Veneto Region, Verona, Italy; 3Centre for Epidemiological Studies on HIV/AIDS in Catalonia (CCIDCAT), Barcelona, Spain; 4Sigma Research, London School of Hygiene and Tropical Medicine, UK; 5Maastricht University, University College Maastricht, The Netherlands

**Background** Comparing rates of sexually transmissible infections (STIs) among men who have sex with men (MSM) in different European countries is challenging due to national differences in reporting systems, healthcare systems, infectious disease surveillance methods, quality of data, and/or levels of social acceptance of homosexual behaviours and openness about homosexuality.

**Methods** From June through August 2010, the European MSM Internet Survey (EMIS) mobilised more than 180 000 respondents from 38 European countries to complete an online questionnaire in one of 25 languages. The questionnaire covered sexual happiness, HIV and STI-testing and diagnoses, unmet prevention needs, interaction with the healthcare system, sexual orientation, healthcare needs in most European countries. In Europe, there is an urgent need to implement or improve sexual healthcare tailored to MSM-specific needs.

**Results** Perceptions on access to free/affordable STI-testing differed across Europe (median: 80%; range: 40–95%); and was substantially correlated with reported recent STI-testing (R² = 0.27). Quality of STI-testing was highly diverse: While blood-testing was common in all participating countries, only Ireland, Malta, and the UK seem to offer penile or particularly anal examinations as standard of care. In all participating countries HIV-positive respondents reported higher rates of both STI-testing and diagnosis. Self-reported STI-screening among men without HIV diagnosis ranged from 10% (Turkey) to 37% (Netherlands). Substantial correlations between rates of testing procedures appropriate for MSM (such as anal or genital swabs) and diagnosed gonorrhoea (R²HIV-pos = 0.24) or Chlamydia infections were observed (R²HIV-pos = 0.50; R²others = 0.29).

**Conclusion** Self-reported testing and diagnosis rates for bacterial STIs suggest high levels of under-diagnosis and unmet sexual healthcare needs in most European countries. In Europe, there is an urgent need to implement or improve sexual healthcare tailored to MSM-specific needs.

**S15.4 RE-EMERGENCE OF LYMPHOGRANULOMA VENEREUM IN EUROPE AND THE PUBLIC HEALTH RESPONSE**

doi:10.1136/sextrans-2011-050102.65

1H Ward, 2H J C de Vries, 3M van de Laar. 1Imperial College, London, UK; 2GGD Amsterdam, The Netherlands; 3European Centre for Disease Prevention and Control, Stockholm, Sweden

**Background** In January 2004, public health officials in the Netherlands noted an outbreak of cases of lymphogranuloma venereum (LGV) among men who have sex with men (MSM). Since then a number of outbreaks and cases have been reported from European countries, North America and Australia. The re-emergence of LGV in
S15.1 Sexually transmitted infections in Europe: coordinating the European STI network
M van de Laar

*Sex Transm Infect* 2011 87: A18-A19
doi: 10.1136/sextrans-2011-050102.62

Updated information and services can be found at:
http://sti.bmj.com/content/87/Suppl_1/A18.3

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
- Syphilis (793)
- Gonorrhoea (806)
- Screening (epidemiology) (985)
- Screening (public health) (984)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/